Vizsgálati helyszín
EUROMEDIS Sp z o o
Szczecin, 70-111, LengyelországEU-13 felzárkózó országMég nincs intézményhez kötve
- 17futó vizsgálat
- 10lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 27 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis13 vizsgálat
- 2. fázis9 vizsgálat
- 1/2. fázis3 vizsgálat
- 1. fázis2 vizsgálat
- Állapot
- Fut, nem toboroz10 vizsgálat
- Lezárult9 vizsgálat
- Toboroz7 vizsgálat
- Leállították1 vizsgálat
- Fő szponzor
- Hoffmann-La Roche7 vizsgálat
- Eli Lilly and Company3 vizsgálat
- Alector Inc.2 vizsgálat
- Zenas BioPharma (USA), LLC2 vizsgálat
- AbbVie1 vizsgálat
- és még 12
Futó vizsgálatok
Toboroz
Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease
NCT07781657· 2. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
NCT07067463· 3. fázis· Zenas BioPharma (USA), LLC· Forrás
Toboroz
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
NCT07299019· 3. fázis· Zenas BioPharma (USA), LLC· Forrás
Toboroz
Safety and Tolerability of IRL757 in Participants With Parkinson's Disease and Apathy
NCT07461220· 1/2. fázis· Integrative Research Laboratories AB· Forrás
Contact: PI Dr. Marcin Ratajczak
Toboroz
A Study in Adults with Parkinson's Disease and a Lack of Interest or Motivation to Test How Different Doses of IRL757 Given for Multiple Days are Tolerated in the Body
2025-523612-37-00· 1. fázis· Integrative Research Laboratories Sweden AB· Forrás
Fut, nem toboroz
Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis
NCT06847724· 3. fázis· Sandoz· Forrás
Fut, nem toboroz
A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)
NCT06402838· 2. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients with Relapsing-remitting Multiple Sclerosis.
2022-501622-37-00· 3. fázis· Celltrion Inc.· Forrás
Toboroz
A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)
NCT06064890· 1/2. fázis· AviadoBio Ltd· Forrás
Fut, nem toboroz
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
NCT05508789· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis
NCT05054140· 2. fázis· Immunic AG· Forrás
Fut, nem toboroz
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)
NCT05147220· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
NCT05704361· 1. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease
NCT04639050· 1/2. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
NCT04548999· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
NCT04544436· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
NCT04035005· 3. fázis· Hoffmann-La Roche· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Fut, nem toboroz
A study to evaluate the safety and long-term biomarker effects of RO7269162 in participants at risk for or at the prodromal stage of Alzheimer’s Disease (AD)
2023-506183-13-00· 2. fázis· F. Hoffmann-La Roche AG· Forrás
Lezárult
Randomised, double-blind, placebo-controlled study to assess safety and efficacy of PRI-002 in patients with MCI or mild dementia due to Alzheimer’s disease (AD)
2022-503148-41-00· 2. fázis· Prinnovation GmbH· Forrás
Leállították
A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease
NCT05744401· 2. fázis· Alector Inc.· Forrás
Lezárult
A study to test long-term safety of Iclepertin in people with schizophrenia who took part in a previous CONNEX study
2024-511560-93-00· 3. fázis· Boehringer Ingelheim International GmbH· Forrás
Lezárult
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease
NCT05063539· 2. fázis· Eli Lilly and Company· Forrás
Lezárult
A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)
NCT04867616· 2. fázis· UCB Biopharma SRL· Forrás
Lezárult
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
NCT04686136· 3. fázis· AbbVie· Forrás
Lezárult
A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease
NCT04592874· 2. fázis· Alector Inc.· Forrás
Lezárult
A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents
NCT04530110· 3. fázis· Teva Branded Pharmaceutical Products R&D LLC· Forrás
Fut, nem toboroz
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
NCT04437511· 3. fázis· Eli Lilly and Company· Forrás
Hibát jelzek